Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Chronic Hepatitis B Clinical Trial

Official title:
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation

Status Completed

Clinical Trial Summary

This study was designed to evaluate and compare the safety and tolerability of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC)/TDF, and entecavir (ETV) in the treatment of hepatitis B patients with decompensated liver disease. Safety was assessed by evaluating adverse events (AEs) and laboratory abnormalities. Efficacy was assessed by evaluating reductions in Child-Pugh-Turcotte (CPT) and Model for End Stage Liver Disease (MELD) scores, reductions in hepatitis B virus (HBV) deoxyribonucleic acid (DNA), changes in liver enzymes, development of drug-resistant mutations, and generation of antibody to virus.

A maximum randomized treatment duration of 168 weeks was planned. Since subjects with decompensated liver disease were enrolled into this study, it was necessary to provide early intervention strategies if profound viral suppression was not expeditiously achieved. For this reason, subjects with a decrease in plasma HBV DNA from baseline of < 2 log_10 copies/mL and plasma HBV DNA > 10,000 copies/mL (or plasma HBV DNA > 1,000 copies/mL for subjects who entered the study with HBV DNA < 10,000 copies/mL) at Week 8 had the option to start open-label FTC/TDF and continue in the study. Subjects with a virologic breakthrough or who had plasma HBV DNA levels remaining > 400 copies/mL (confirmed) at or after 24 weeks of treatment could have been unblinded at the investigator's discretion for selection of alternative anti-HBV therapy that may have included open-label FTC/TDF. If study drug was permanently discontinued, immediate initiation of another anti-HBV regimen was strongly recommended.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00298363
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	April 2006
Completion date	April 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04496882` - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue	Phase 4
Completed	`NCT04083716` - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults	Phase 1
Not yet recruiting	`NCT03038802` - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection	Phase 1/Phase 2
Completed	`NCT05310487` - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects	Phase 1
Recruiting	`NCT06070051` - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy	Phase 1
Terminated	`NCT05001022` - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects	Phase 1
Recruiting	`NCT04139850` - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting	`NCT05343481` - Efficacy of VTP-300 in Chronic Hepatitis B Infection	Phase 2
Not yet recruiting	`NCT05490836` - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients	N/A
Recruiting	`NCT04543565` - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study	Phase 3
Active, not recruiting	`NCT02894918` - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs	Phase 4
Not yet recruiting	`NCT02793791` - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients	N/A
Recruiting	`NCT02287857` - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B	N/A
Recruiting	`NCT01965418` - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial	Phase 4
Recruiting	`NCT01491295` - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients	Phase 4
Terminated	`NCT01872988` - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma	Phase 3
Recruiting	`NCT01487876` - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients	Phase 2
Not yet recruiting	`NCT01436539` - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Phase 4
Completed	`NCT01531166` - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon	N/A
Recruiting	`NCT01360892` - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography	N/A